Zaltrap ‘unlikely to beat Avastin’ despite EU approval and launch in mCRC

The European Commission has granted marketing authorization to Sanofi and Regeneron Pharmaceuticals' Zaltrap (aflibercept) for previously treated metastatic colorectal cancer. Sanofi told Scrip it anticipates that the drug will be first available in Germany, Austria and the Nordic countries but would not comment further on its commercial strategy. Datamonitor analyst James Wade, however, believes that the commercial prospects for the drug may be limited.

The European Commission has granted marketing authorization to Sanofi and Regeneron Pharmaceuticals' Zaltrap (aflibercept) for previously treated metastatic colorectal cancer. Sanofi told Scrip it anticipates that the drug will be first available in Germany, Austria and the Nordic countries but would not comment further on its commercial strategy. Datamonitor analyst James Wade, however, believes that the commercial prospects for the drug may be limited.

Looking to the companies' additional plans for Zaltrap, Mr Wade believes that a label, expansion into the first-line CRC setting...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anticancer

After Gilead Deal, Hookipa Hangs Up Its Hat

 
• By 

The Austrian firm is delisting from the NASDAQ and closing down.

Genentech Gets Columvi Complete Response Following ODAC’s No

 
• By 

Seeking to move Columvi into second-line DLBCL, Genentech got an FDA letter saying the Phase III STARGLO study’s benefits may have been driven by results in Asian enrollees.

BMS’s Reblozyl Misses Primary Endpoint In Myelofibrosis Anemia

 

The drugmaker announced topline results from the Phase III INDEPENDENCE trial, which did meet key secondary endpoints.

AI-First, Big Pharma, Chinese Firms In Race - What’s Ahead For PRMT5 Inhibitors

 
• By 

As AI-driven firms including Insilico, big pharmas J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?

More from Therapeutic Category

Insmed’s New R&D Site Focused On ‘Synthetic Rescue’

 

A new small-molecule approach to turning on beneficial genes to counteract disease-causing mutations is being pioneered by Insmed’s UK-based scientists.

AI-First, Big Pharma, Chinese Firms In Race - What’s Ahead For PRMT5 Inhibitors

 
• By 

As AI-driven firms including Insilico, big pharmas J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?

BMS/Pfizer To Sell Discounted Eliquis Direct – And Other Drugmakers May Follow Suit

 

Analysts see the new strategy as a way to address pressure from the Trump administration’s most favored nation drug pricing proposals.